People with mild cognitive impairment who have core clinical features of Lewy body dementia have imaging biomarker abnormalities that are linked to clinical phenotypes.
Why this matters
This novel study uses two imaging modalities to identify biomarkers that are sensitive to different pathologic processes in prodromal Lewy body dementia. The findings suggest that amyloid-β positron emission tomography and dopamine transporter imaging are complementary in characterizing clinical phenotypes of individuals at risk of progressing to Lewy body dementia.
The finding that amyloid-β positivity is linked to worse cognitive function highlights a potential therapeutic target for slowing the progression from prodromal to overt Lewy body dementia.